STUDY OF ANTICANCER ACTIVITY OF BRUSATOL, CURCUMIN AND PARAQUAT AGAINST CANCER CELL LINE THROUGH WESTERN BLOTTING STUDY ANALYSIS

: The present study scrutinized the anticancer activity of paraquat, curcumin, paraquat + curcumin; and brusatol + curcumin + paraquat against human colon adenocarcinoma cell line (Caco-2) and human pulmonary carcinoma cell line (NCI-H292). In adenocarcinoma cell line study, at the presence of curcumin, significant activation (+++) of Nuclear factor erythroid 2-related factor 2 (Nrf2) was noticed. In the combination of Brusatol + Curcumin + Paraquat, less activation (+) of Nuclear factor erythroid 2-related factor 2 (Nrf2) was observed. But in Pulmonary Carcinoma, at the combination of Brusatol + Curcumin + Paraquat, less activation (+) of Nuclear factor erythroid 2-related factor 2 (Nrf2) was observed. Commonly, in both cancer cell line, no activation (-) of Nuclear factor erythroid 2-related factor 2 (Nrf2) was seen in control. This study confirmed that the effect of anticancer of curcumin and its combinations. controls the switching off of Nrf2 activation of gene expression. GSK3β phosphorylates Fyn at an unknown threonine residue(s), leading to the nuclear localization of Fyn. Fyn phosphorylates Nrf2 tyrosine 568, resulting in the nuclear export of Nrf2, binding with INrf2, and degradation of Nrf2. The switching on and off of Nrf2 protects cells against free radical damage, prevents apoptosis, and promotes cell survival. The western blotting analysis proved that the combination of paraquat, curcumin, paraquat + curcumin; and brusatol + curcumin + paraquat are effective against human colon adenocarcinoma cell line (Caco-2) and human pulmonary carcinoma cell lines.